Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 370

1.

[Rituximab therapy for severe pediatric systemic lupus erythematosus].

Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J.

Zhonghua Er Ke Za Zhi. 2012 Sep;50(9):697-704. Chinese.

PMID:
23158822
2.

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.

Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V.

Nephrol Dial Transplant. 2011 Dec;26(12):3987-92. doi: 10.1093/ndt/gfr109. Epub 2011 Mar 8.

3.

Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F.

Rheumatol Int. 2013 Mar;33(3):809-13. doi: 10.1007/s00296-011-2239-6. Epub 2011 Nov 19.

PMID:
22101555
4.

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.

Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.

Lupus. 2010 Feb;19(2):213-9. doi: 10.1177/0961203309351541. Epub 2009 Dec 4.

PMID:
19965944
5.

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.

Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D'Cruz DP.

Lupus. 2013 May;22(6):574-82. doi: 10.1177/0961203313483376. Epub 2013 Apr 30.

PMID:
23632989
6.

Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.

Jovancevic B, Lindholm C, Pullerits R.

Lupus. 2013 Jun;22(7):664-74. doi: 10.1177/0961203313485489. Epub 2013 Apr 23. Review.

PMID:
23612795
7.

Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.

Ale'ed A, Alsonbul A, Al-Mayouf SM.

Rheumatol Int. 2014 Apr;34(4):529-33. doi: 10.1007/s00296-013-2896-8. Epub 2013 Nov 12.

PMID:
24218286
8.

B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.

Harvey PR, Gordon C.

BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8.

PMID:
23456653
9.

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, Boffa JJ, Karras A, Masse V, Lesavre P, Elie C, Brocheriou I, Knebelmann B, Noël LH, Fakhouri F.

Clin J Am Soc Nephrol. 2009 Mar;4(3):579-87. doi: 10.2215/CJN.04030808. Epub 2009 Mar 4.

10.

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.

J Rheumatol. 2008 May;35(5):826-33. Epub 2008 Apr 1.

PMID:
18398943
11.

Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.

Jiang B, Li T, Guo L, Shen H, Ye S, Chen S.

J Clin Rheumatol. 2015 Aug;21(5):244-50. doi: 10.1097/RHU.0000000000000273.

12.

The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.

Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, Tullus K.

Lupus. 2015 Jan;24(1):10-7. doi: 10.1177/0961203314547793. Epub 2014 Aug 12.

PMID:
25117653
13.

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide.

Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, Moorthy N.

Pediatr Rheumatol Online J. 2014 Jan 14;12:3. doi: 10.1186/1546-0096-12-3.

14.

B cell biomarkers of rituximab responses in systemic lupus erythematosus.

Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, Ponchel F, Rawstron AC, Emery P.

Arthritis Rheum. 2011 Oct;63(10):3038-47. doi: 10.1002/art.30466.

15.

Rituximab therapy for childhood-onset systemic lupus erythematosus.

Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group.

J Pediatr. 2006 May;148(5):623-627. Erratum in: J Pediatr. 2006 Oct;149(4):586.

PMID:
16737873
16.

Rituximab therapy for juvenile-onset systemic lupus erythematosus.

Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G.

Pediatr Nephrol. 2008 Mar;23(3):413-9. Epub 2007 Dec 19.

17.

Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.

Tsai MJ, Chou CW, Lin FC, Chang SC.

Lupus. 2012 Jul;21(8):914-8. doi: 10.1177/0961203312436855. Epub 2012 Jan 27.

PMID:
22287506
18.

The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.

Galarza-Maldonado C, Kourilovitch MR, Molineros JE, Cardiel MH, Zurita L, Soroka NF, Yagur VY, Doukh N, Cervera R.

Autoimmun Rev. 2010 Dec;10(2):108-11. doi: 10.1016/j.autrev.2010.08.012. Epub 2010 Sep 8.

PMID:
20804861
19.

Intravenous cyclophosphamide pulse therapy in Japanese children with systemic lupus erythematosus.

Igarashi T, Igarashi T, Shimizu A, Itoh Y.

J Nippon Med Sch. 2013;80(5):396-400.

20.

[Rituximab in pediatric patients with systemic lupus erythematosus].

Pavón-Sánchez JM, Sánchez-Sánchez LM.

Gac Med Mex. 2013 Sep-Oct;149(5):492-6. Spanish.

Supplemental Content

Support Center